Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TranspoCART19 |
Synonyms | |
Therapy Description |
Limited information is currently available on a TranspoCART19, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and containing TNFRSF9 (4-1BB) co-stimulatory region, CD3z, and huEGFRt (Jun 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TranspoCART19 | Transpo-CART19|Transpo CART19 | CD19 Immune Cell Therapy 62 | Limited information is currently available on a TranspoCART19, a putative chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and containing TNFRSF9 (4-1BB) co-stimulatory region, CD3z, and huEGFRt (Jun 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06378190 | Phase Ib/II | TranspoCART19 | Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19) | Recruiting | ESP | 0 |